Top 5 Stocks to Buy Now
→ A drilling crew just broke a record nobody expected (From Behind the Markets) (Ad)tc pixel
NASDAQ:DRTS

Alpha Tau Medical Q1 2026 Earnings Report

Alpha Tau Medical logo
$10.84 -0.33 (-2.91%)
As of 11:37 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Alpha Tau Medical EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.13
Beat/Miss
Missed by -$0.13
One Year Ago EPS
N/A

Alpha Tau Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.05 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alpha Tau Medical Announcement Details

Quarter
Q1 2026
Date
5/18/2026
Time
Before Market Opens
Conference Call Date
Monday, May 18, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Alpha Tau Medical's Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Alpha Tau Medical's Q1 2026 Press ReleasePress Release
(6-K)

Alpha Tau Medical Earnings Headlines

Alpha Tau Medical Shareholders Back Board, CEO Dual Role and Auditor at June 2026 AGM
June 25 at 4:51 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/alpha-tau-medical-shareholders-back-board-ceo-dual-role-and-auditor-at-june-2026-agm?utm_source=marketbeat.com&utm_medium=referral
Alpha Tau Treats First Recurrent Glioblastoma Patient Outside U.S. With Alpha DaRT in Israel
June 23 at 5:11 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/alpha-tau-treats-first-recurrent-glioblastoma-patient-outside-u-s-with-alpha-dart-in-israel?utm_source=marketbeat.com&utm_medium=referral
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
June 26 at 1:00 AM  |  Profits Run (Ad)
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel
June 23 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/23/3315968/0/en/alpha-tau-successfully-treats-first-recurrent-glioblastoma-patient-outside-of-the-united-states-with-alpha-dart-at-hadassah-university-medical-center-in-israel.html
Alpha Tau Medical: A Lot Of Shots On Goal
June 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4914504-alpha-tau-medical-a-lot-of-shots-on-goal
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease ...
June 11, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/alpha-tau-receives-fda-clearance-to-complete-enrollment-in-regain-recurrent-glioblastoma-trial-and-add-two-u-s-clinical-sites-early-interim-results-showed-100-local-disease-control-1036242209
See More Alpha Tau Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alpha Tau Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alpha Tau Medical and other key companies, straight to your email.

About Alpha Tau Medical

Alpha Tau Medical (NASDAQ:DRTS) is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors. Alpha DaRT implants release alpha-emitting atoms that diffuse a few millimeters into the tumor, providing localized radiation doses that have shown promising preclinical and early clinical anti‐tumor activity. Alpha Tau Medical has secured Breakthrough Device designation from the U.S. Food and Drug Administration for certain cancer types and is advancing its pipeline through multi‐center trials in Europe and Israel.

Alpha Tau Medical collaborates with major oncology centers and academic institutions to conduct its clinical programs and to explore combination approaches with immunotherapies and other treatment modalities. The company has expanded its operational footprint beyond Israel, engaging regulatory and commercial partners in Europe while preparing for potential U.S. market entry. Through its focused R&D efforts and strategic alliances, Alpha Tau Medical seeks to establish alpha‐particle brachytherapy as a new standard of care for patients with challenging solid tumors.

View Alpha Tau Medical Profile
Earnings Tools